Table 2. Follow up and outcomes (n = 21).

No. (%) or Median (95% CI)
Safety and tolerance evaluation
At least one Adverse Event Δ	13 (61.9%)
At least one drug-related Adverse Event Λ	4 (19.0%)
At least one Adverse Event leading to study drug discontinuation ¥	2 (9.5%)
At least one Serious Adverse Event Θ	8 (38.1%)
At least one Serious Adverse Event with death	5 (23.8%)
Allergy	1 (4.7%)
Electrolyte disturbances
Deep hypokalemia (<2.5 mmol/L)	0
Renal toxicity
Serum creatinine increase (doubled baseline)	3 (14.3%)
Serum creatinine increase (threefold baseline)	2 (9.5%)
Need for dialysis	0
Other Outcomes
Disappearance of Candida colonization	5 (23.8%)
Candidemia	1 (4.7%)
Length of ICU stay (days)	13 (8–26)
Length of hospital stay (days)	21 (10–27)
ICU mortality	5 (23.8%)

Abbreviations: ICU, Intensive Care Unit

^¥ One patient with transient and one patient with definitive study drug discontinuation

^Δ Total number of adverse events (one patient may have more than one adverse event) n = 24 (thoracic disorders n = 5; infections n = 5; blood and lymphatic system disorders n = 3; general disorders n = 3; gastrointestinal disorders n = 3; cardiac disorders n = 2; vascular disorders n = 1; hepatobiliary disorders n = 1; surgical and medical procedures n = 1). Classified as mild (n = 10); moderate (n = 1); severe (n = 13).

^Λ Leukopaenia/neutropaenia/Thrombocytopenia n = 2; Supraventricular tachycardia n = 1; Hypotension (allergy) n = 1

^Θ Total number of serious adverse events (one patient may have more than one serious adverse event) n = 14 (infections n = 5; blood and lymphatic system disorders n = 2; general disorders n = 2; respiratory disorders n = 2; gastrointestinal disorders n = 2; cardiac disorders n = 1).